| Title |
Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece
|
|---|---|
| Published in |
Cancer Management and Research, April 2013
|
| DOI | 10.2147/cmar.s43373 |
| Pubmed ID | |
| Authors |
V Fragoulakis, E Kastritis, T Psaltopoulou, N Maniadakis |
| Abstract |
Multiple myeloma is a hematologic malignancy that incurs a substantial economic burden in care management. Since most patients with multiple myeloma eventually relapse or become refractory to current therapies (rrMM), the aim of this study was to assess the cost-effectiveness of the combination of lenalidomide-dexamethasone, relative to bortezomib alone, in patients suffering from rrMM in Greece. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 66 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 22% |
| Student > Master | 13 | 19% |
| Other | 11 | 16% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Doctoral Student | 5 | 7% |
| Other | 7 | 10% |
| Unknown | 10 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 34% |
| Economics, Econometrics and Finance | 12 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Psychology | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 6 | 9% |
| Unknown | 12 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2022.
All research outputs
#4,735,664
of 23,515,383 outputs
Outputs from Cancer Management and Research
#191
of 2,032 outputs
Outputs of similar age
#39,469
of 201,782 outputs
Outputs of similar age from Cancer Management and Research
#1
of 6 outputs
Altmetric has tracked 23,515,383 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,032 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 201,782 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them